Research programme: anti-inducible T-cell co-stimulator monoclonal antibodies - MedImmune/Japan Tobacco

Drug Profile

Research programme: anti-inducible T-cell co-stimulator monoclonal antibodies - MedImmune/Japan Tobacco

Alternative Names: Anti-ICOS

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 10 May 2017 Anti-inducible T-cell co-stimulator monoclonal antibodies is still in preclinical development for Autoimmune disorders and Inflammation in USA and Japan (Japan Tobacco pipeline, May 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top